Changes of Immunoglobulin in TACE Treatment of Hepatocellular Carcinoma and Its Value in Predicting Curative Effect

Lanzhu YAN; Shunyi QIAO; Yanli ZHANG; Erqiang ZHAO; Hu YANG; Jing LIN; Haiyan FU

doi:10.12259/j.issn.2095-610X.S20240418

Volume 45 Issue 4

Apr. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(4): 128-134

Lanzhu YAN, Shunyi QIAO, Yanli ZHANG, Erqiang ZHAO, Hu YANG, Jing LIN, Haiyan FU. Changes of Immunoglobulin in TACE Treatment of Hepatocellular Carcinoma and Its Value in Predicting Curative Effect[J]. Journal of Kunming Medical University, 2024, 45(4): 128-134. doi: 10.12259/j.issn.2095-610X.S20240418

Citation:

Lanzhu YAN, Shunyi QIAO, Yanli ZHANG, Erqiang ZHAO, Hu YANG, Jing LIN, Haiyan FU. Changes of Immunoglobulin in TACE Treatment of Hepatocellular Carcinoma and Its Value in Predicting Curative Effect[J]. Journal of Kunming Medical University, 2024, 45(4): 128-134. doi: 10.12259/j.issn.2095-610X.S20240418

Citation:

Lanzhu YAN, Shunyi QIAO, Yanli ZHANG, Erqiang ZHAO, Hu YANG, Jing LIN, Haiyan FU. Changes of Immunoglobulin in TACE Treatment of Hepatocellular Carcinoma and Its Value in Predicting Curative Effect[J]. Journal of Kunming Medical University, 2024, 45(4): 128-134. doi: 10.12259/j.issn.2095-610X.S20240418

PDF( 834 KB)

Changes of Immunoglobulin in TACE Treatment of Hepatocellular Carcinoma and Its Value in Predicting Curative Effect

doi: 10.12259/j.issn.2095-610X.S20240418

Lanzhu YAN¹,
Shunyi QIAO¹,
Yanli ZHANG¹,
Erqiang ZHAO¹,
Hu YANG¹,
Jing LIN^{2
,
,},
Haiyan FU^{1, 2, 3}

1.
Dept. of Laboratory and Pathology
2.
Dept. of Internal Medicine，Hebei Armed Police Corps Hospital，Shijiazhuang Hebei 050080
3.
Dept. of Oncology，The 1st Hospital of Hebei Medical University，Shijiazhuang Hebei 050030，China

Received Date: 2023-11-29
Available Online: 2024-04-03
Publish Date: 2024-04-29

Abstract

Abstract

Objective To analyze the changes of immunoglobulin （Ig） during the process of transcatheter arterial chemoembolization （TACE） for hepatocellular carcinoma （HCC） and predict the value of treatment efficacy. Methods A total of 100 HCC patients in Hebei Armed Police Corps Hospital from January 2022 to January 2023 were selected as the liver cancer group, 50 patients with benign liver disease were selected as the benign group, and 50 healthy volunteers were selected as the control group. The general data, serum Ig （IgA, IgG, IgM） and conventional tumor markers [alpha-fetoprotein （AFP）, cytokeratin 19 （CK19）, Golgi protein 73 （GP73）], and the correlation between serum Ig and conventional tumor markers in the HCC group was analyzed. The serum levels and changes of Ig and conventional tumor markers in patients with different efficacy after TACE treatment in the liver cancer group were compared before and after treatment. The correlation between the changes of serum Ig and conventional tumor markers and the efficacy of ACE was analyzed, and the predictive value of ACE prediction scheme with or without Ig was compared. Results The levels of IgA, IgG and IgM in liver cancer group were lower than those in benign group and control group; the levels of AFP, CK19 and GP73 in liver cancer group were higher than those in benign group and control group; the levels of IgA, IgG and IgM in benign group were lower than those in control group; the levels of AFP, CK19 and GP73 in benign group were higher than those in control group （P < 0.05）. Serum IgA, IgG and IgM levels were negatively correlated with serum AFP, CK19 and GP73 levels in HCC group （P < 0.05）. The serum levels of IgA, IgG and IgM in patients with poor TACE treatment were lower than those in patients with good efficacy before and after treatment, the levels of AFP, CK19 and GP73 were higher than those in patients with good efficacy, and △IgA, △IgG, △IgM, △AFP, △CK19 and △GP73 were lower than those in patients with good efficacy （P < 0.05）. △IgA, △IgG, △IgM, △AFP, △CK19, △GP73 were positively correlated with the therapeutic effect of TACE （P < 0.05）. The area under the curve （AUC） of △IgA, △IgG, △IgM, △AFP, △CK19 and △GP73 for predicting poor TACE efficacy in HCC patients were 0.777, 0.784, 0.793, 0.779, 0.710 and 0.746, respectively. Compared with the non-IG prediction scheme （△AFP, △CK19, △GP73 combined prediction）, the AUC with Ig prediction scheme （△IgA, △IgG, △IgM, △AFP, △CK19, △GP73 combined prediction） was significantly increased in predicting poor TACE efficacy in HCC patients. Both NRI and IDI were > 0 （P < 0.05）. Conclusion The levels of serum IgA, IgG and IgM in HCC patients increased during TACE treatment, and the changes of each index can provide a reliable basis for clinical prediction of TACE efficacy.
- Hepatocellular carcinoma,
- Immunoglobulin,
- Hepatic artery chemoembolization for liver cancer,
- Curative effect,
- Forecast

FullText(HTML)

References(22)

References

[1]	Rumgay H,Arnold M,Ferlay J,et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol,2022,77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021
[2]	McGlynn K A, Petrick J L, El-Serag H B. Epidemiology of hepatocellular carcinoma[J]. Hepatology, 2021, 73 Suppl 1（Suppl 1）: 4-13.
[3]	Feng J,Li J,Wu L,et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res,2020,39(1):126. doi: 10.1186/s13046-020-01629-4
[4]	Zou H,Li M,Lei Q,et al. Economic burden and quality of life of hepatocellular carcinoma in greater China: A systematic review[J]. Front Public Health,2022,10(1):801981.
[5]	Zhou H,Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J]. Biosci Trends,2021,15(3):155-160. doi: 10.5582/bst.2021.01091
[6]	Chang Y,Jeong S W,Young Jang J,et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci,2020,21(21):8165. doi: 10.3390/ijms21218165
[7]	Liu B,Zhang Y,Chen H,et al. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma[J]. Cochrane Database Syst Rev,2022,1(1):CD013345.
[8]	黄翠,余方方,黎笔娥,等. 原发性肝癌患者免疫球蛋白水平与介入治疗后肝纤维化的相关性[J]. 临床消化病杂志,2022,34(5):375-379.
[9]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志,2020,28(2):112-128.
[10]	中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华医学杂志,2021,101(24):1848-1862.
[11]	European Association for the Study of the Liver. EASL clinical practice guidelines on the management of benign liver tumours[J]. J Hepatol,2016,65(2):386-398. doi: 10.1016/j.jhep.2016.04.001
[12]	Schwartz LH,Litière S,de Vries E,et al. RECIST 1.1-update and clarification: From the RECIST committee[J]. Eur J Cancer,2016,62(1):132-137.
[13]	Ajoolabady A,Tang D,Kroemer G,et al. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy[J]. Br J Cancer,2023,128(2):190-205. doi: 10.1038/s41416-022-01998-x
[14]	游长金,邓娟,崔俐莉. MRI参数联合血清MIF、miR-1203在肝细胞肝癌早期诊断中的价值及与疗效的关系[J]. 中国医师杂志,2021,23(5):734-738,743.
[15]	施青青,孙幸,吴蔚,等. 血清免疫球蛋白检测在急性白血病患者中的临床意义[J]. 检验医学与临床,2020,17(20):2975-2977,2981.
[16]	金宇,刘晓玲,黄怡丹. 免疫球蛋白和自身抗体在乙型肝炎肝硬化发病和进展中的表达及与预后的关系[J]. 中国现代医学杂志,2023,33(4):56-61.
[17]	祁燕伟,刘春云,刘立,等. HIV/HBV共感染患者免疫功能与肝组织纤维化的相关性研究[J]. 国际检验医学杂志,2023,44(1):34-39.
[18]	Zhuo J Y,Lu D,Tan W Y,et al. CK19-positive hepatocellular carcinoma is a characteristic subtype[J]. J Cancer,2020,11(17):5069-5077. doi: 10.7150/jca.44697
[19]	潘俊均,黄仙圣,岑伟明,等. AFP、AFP-L3%、DCP与GP73联合检测辅助诊断肝炎、肝癌临床价值[J]. 分子诊断与治疗杂志,2021,13(10):1579-1582.
[20]	Huppert P. Transarterial chemoembolization of hepatocellular carcinoma[J]. Radiologe,2022,62(3):225-233. doi: 10.1007/s00117-022-00972-1
[21]	张永涛,谭业栋,张立成,等. 微波消融术联合经导管动脉化疗栓塞对原发性肝癌患者免疫功能、肝功能与生存情况的影响[J]. 癌症进展,2021,19(18):1903-1906.
[22]	程媛,胡洋,邱发凯. 经导管动脉化疗栓塞术治疗原发性肝癌的临床疗效[J]. 检验医学与临床,2022,19(5):697-700.

Relative Articles(20)

Relative Articles

[1]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[2]	Xinyi MEN, Jing ZHAO, Yongchun SHEN, Hui JI, Xiuxia WANG. The Relationship between Peripheral Blood Immunoglobulin，Erythrocyte Sedimentation Rate，Homocysteine and the Degree of Central Nervous System Vasculitis in Children and Their Influence on Prognosis. Journal of Kunming Medical University, 2024, 45(): 1-7.
[3]	Chunyan LIU, Bingqing CHANG, Chao LI, Xin REN, Xiaoqin LIU. The Relationship between T Lymphocyte Subsets and Pathological Characteristics of Acute Myeloid Leukemia and the Value of Predicting Chemotherapy Prognosis. Journal of Kunming Medical University, 2024, 45(5): 1-7.
[4]	Xiaoling YANG, Zhen LIU, Yu WANG, Jing WANG. The Predictive Value of sFlt-1，SDC4，and sST2 on the Therapeutic effect of Children with Purpuric Nephritis. Journal of Kunming Medical University, 2024, 45(): 1-6.
[5]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[6]	Yan WANG, Rong DING, Lvling ZHANG, Ruohua WANG, Xiaoling ZHAO, Na MA. Efficacy of Blood Transfusion Combined with Chemoradiotherapy in Patients with Colorectal Cancer and its Effect on Tumor Markers and T Lymphocyte Levels. Journal of Kunming Medical University, 2022, 43(8): 61-65. doi: 10.12259/j.issn.2095-610X.S20220809
[7]	Tian Bo Yan , Yang Qin Ling , Zhang Jiao Qiong , Han Na , Liu Shao Hua . The Curative Effect of Auxiliary Hepatic Arterial Chemoembolization in the Treatment of Microvascular Invasion of Hepatocellular Carcinoma. Journal of Kunming Medical University, 2018, 39(08): 86-92.
[8]	Hu Wei Hua . The Observation of Clinical Effect of Using Ambroxol in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Kunming Medical University,
[9]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[10]	Shang Xue Qin . . Journal of Kunming Medical University,
[11]	Ai Yi Qin . . Journal of Kunming Medical University,
[12]	Ai Yi Qin . . Journal of Kunming Medical University,
[13]	Li Heng . . Journal of Kunming Medical University,
[14]	Lu Xiao Tao . . Journal of Kunming Medical University,
[15]	Zhu Li Xian . . Journal of Kunming Medical University,
[16]	Yang Wen Ju . . Journal of Kunming Medical University,
[17]	Hu Hai Yan . . Journal of Kunming Medical University,
[18]	Liu Yue Bo . . Journal of Kunming Medical University,
[19]	Hu Wan Qin . . Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,